50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study
Recommended Citation
Pinter A, Stein-Gold L, Bagel J, Tyring SK, Vender R, Reich A, Pavlovsky L, Kaldas MI, Wu T, Patel M, Papp KA. 50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study. J Am Acad Dermatol 2024; 91(3):AB165.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: The phase-4 IMMpulse (NCT04908475) study demonstrated superior efficacy of risankizumab versus apremilast in systemic-eligible adult patients with moderate plaque psoriasis (ref). Methods: At baseline, 118 patients received risankizumab (150 mg), and 234 patients received apremilast (induction phase followed by 30 mg BID) for 16-weeks (Period-A). This analysis compared the proportion of patients achieving Psoriasis Symptoms Scale (PSS) score 0/1 (none to mild: pain, redness, itch, and burning), high levels of satisfaction assessed by the Treatment Satisfaction Questionnaire for Medication version-9 (TSQM-9), and Dermatology Life Quality Index (DLQI) 0/1. Analyses included individual item-level results comparing risankizumab versus apremilast at weeks-4 and -16. Results: Patient characteristics were comparable across treatments. At week-16 numerically higher proportion of risankizumab compared to apremilast-treated patients achieved: • PSS 0/1 (pain [88.1%/58.5%], redness [83.1%/39.3%], itching [82.2%/36.8%], and burning [85.6%/54.7%]) • very or extremely satisfied/easy/convenient/certain via TSQM-9 (medicine to prevent/treat condition [71.2%/17.1%], medication relieves symptoms [68.6%/16.2%], time medicine takes to start working [66.1%/9.8%], easy/difficult to use medicine [69.5%/41.5%], easy/difficult to plan medicine use [65.3%/32.5%], convenient/inconvenient to take medicine [71.2%/34.6%], confident medicine is good [85.6%/30.8%], certain good things outweigh bad [79.7%/28.6%], and satisfied/dissatisfied with medicine [78.0%/19.2%]). • DLQI 0/1 across all DLQI items. At week-4, consistent results were seen. Conclusion: A higher proportion of risankizumab-treated patients achieved symptom resolution, high levels of satisfaction across all TSQM-9 questions, with little to no impact on quality of life on individual DLQI items compared to apremilast-treated patients after 4 and 16 weeks of treatment.
Volume
91
Issue
3
First Page
AB165
